Malignant neoplasm of breast

SABCS 2025 Highlights: Celcuity’s Phase 3 VIKTORIA-1 Updates and Relay PI3K Inhibitor News

2 weeks ago talkbio0Tagged Celcuity, gedatolisib, Malignant neoplasm of breast, Phase 3, PI3 K inhibitors, PIK3CA gene, Relay Device, SABCS25, VIKTORIA-1, wild-type

SABCS25; Celcuity; VIKTORIA-1; gedatolisib; PIK3CA wild-type; Phase 3; breast cancer; Relay; PI3K inhibitors

NiKang Therapeutics Presents NKT5097: First-in-Class CDK2/4 Dual Degrader at SABCS 2025

3 weeks ago talkbio0Tagged Cancer Therapeutic Procedure, CDK2/4 degrader, Malignant neoplasm of breast, NiKang Therapeutics, SABCS

NiKang Therapeutics; NKT5097; CDK2/4 degrader; SABCS 2025; cancer therapy; breast cancer

Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial

3 weeks ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, hormone receptor-positive, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, phase III lidERA trial, Recurrence Risk, Roche (company), San Antonio Breast Cancer Symposium

Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium

Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)

1 month ago talkbio0Tagged agentic AI, AI-guided, AWS HealthLake, Clinical Decision Support, DNA Integration, healthcare workflow, Malignant neoplasm of breast, Microsoft Teams, multi-agent systems, Neoplasms, Precision Medicine

agentic AI; breast cancer treatment; oncology; clinical decision support; multi-agent systems; healthcare workflow automation; personalized medicine; AWS HealthLake; Microsoft Teams integration; AI-guided treatment planning

Novartis Raises Sales Targets for Key Cancer Drugs, Tweaks Yearly Growth Guidance

1 month ago talkbio0Tagged cancer drugs, Drug Industry, Kisqali, leukemia, Malignant neoplasm of breast, Novartis, peak sales, Pluvicto, sales guidance, Scemblix

Novartis; Kisqali; Scemblix; Pluvicto; sales guidance; peak sales forecast; cancer drugs; breast cancer; leukemia; pharmaceutical industry

Roche’s Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial

1 month ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, Malignant neoplasm of breast, Oral SERD, Phase 3 trial, recurrence prevention, Roche (company)

Roche; oral SERD; giredestrant; Phase 3 trial; early breast cancer; ER-positive; HER2-negative; disease-free survival; adjuvant therapy; recurrence prevention

Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies

1 month ago talkbio0Tagged alnodesertib, ART6043, Artios Pharma, Cancer Therapeutic Procedure, cellular response to DNA damage stimulus, Clinical Trials, Colorectal Carcinoma, DDR, investors, Malignant neoplasm of breast, Oncology Pipeline, Pancreatic carcinoma, Series D financing

Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials

ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions

2 months ago talkbio0Tagged 2025, ADCs, Administration occupational activities, Antibody-Drug Conjugates, Biological Markers, chemo-displacement, Datopotamab deruxtecan, Datroway, Enhertu, ESMO, HER2-positive, Limited stage (cancer stage), Malignant neoplasm of breast, Toxicity aspects, trastuzumab, Triple Negative Breast Neoplasms

ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management

Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025

2 months ago talkbio0Tagged ER-positive, giredestrant, HER2-negative, Malignant neoplasm of breast, Oral SERD, Phase 3 trial, Progression-Free Survival, Roche (company), Selective Estrogen Receptor Down Regulator

Roche; SERD; giredestrant; breast cancer; ESMO 2025; progression-free survival; oral SERD; ER-positive; HER2-negative; phase 3 trial

Roche’s Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial

3 months ago talkbio0Tagged advanced breast cancer, Clinical Research, ER-positive, giredestrant, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, Phase 3 Clinical Trials, Progression-Free Survival, Roche (company)

Roche; oral SERD; giredestrant; progression-free survival; pivotal study; breast cancer; ER-positive; endocrine therapy; Phase III trial; advanced breast cancer